Zobrazeno 1 - 10
of 3 814
pro vyhledávání: ''
Autor:
Stefanie D. Krens, Wim van Boxtel, Carla M.L. van Herpen, Sasja F. Mulder, Frank G A Jansman, Maike J. M. Uijen, Ingrid M.E. Desar, Nielka P. van Erp
Publikováno v:
International Journal of Cancer, 150, 308-316
International Journal of Cancer, 150, 2, pp. 308-316
International Journal of Cancer, 150(2), 308-316. Wiley
International Journal of Cancer, 150, 2, pp. 308-316
International Journal of Cancer, 150(2), 308-316. Wiley
Contains fulltext : 249093.pdf (Publisher’s version ) (Open Access) Cabozantinib is registered in fixed 60 mg dose. However, 46% to 62% of patients in the registration studies needed a dose reduction due to toxicity. Improved clinical efficacy has
Autor:
Jerry A. Shields, Maura Di Nicola, Basil K. Williams, Jing Hua, Arman Mashayekhi, Carol L. Shields, Vladislav P. Bekerman
Publikováno v:
Ophthalmology Retina. 6:80-88
Purpose To report the efficacy of photodynamic therapy (PDT) for management of retinal hemangioblastoma. Design Retrospective case series. Participants Seventeen patients with retinal hemangioblastoma treated with PDT. Methods The medical records of
Autor:
Guilherme Cantuaria, Paul DiSilvestro, Kirsty Rhodes, Lucy Gilbert, Johanna Mäenpää, Christian Marth, Maria Jesus Rubio Pérez, Koji Matsumoto, Claire Garnier-Tixidre, Ayumi Shikama, Isabelle Ray-Coquard, Philipp Harter, Daniel M. Anderson, Magdalena Sikorska, Francesco Raspagliesi, Ignace Vergote, Mario Ouwens, Robert Hettle, Domenica Lorusso, Kathleen N. Moore, Andres Poveda, Nicoletta Colombo, Ronnie Shapira-Frommer
Publikováno v:
European Journal of Cancer. 157:415-423
BACKGROUND: In the absence of randomised head-to-head trials, we conducted a population-adjusted indirect treatment comparison (PA-ITC) of phase III trial data to evaluate the relative efficacy and safety of maintenance olaparib and bevacizumab alone
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-8 (2021)
BMC Cancer
BMC cancer, Vol. 21, no. 1, p. 1204 (2021)
BMC cancer, Vol. 21, no. 1, p. 1204 [1-8] (2021)
BMC Cancer
BMC cancer, Vol. 21, no. 1, p. 1204 (2021)
BMC cancer, Vol. 21, no. 1, p. 1204 [1-8] (2021)
Background Trastuzumab emtansine (T-DM1) is indicated as second-line treatment for human epidermal growth factor receptor 2 (HER2)-positive metastatic or unresectable locally advanced breast cancer, after progression on trastuzumab and a taxane-based
Autor:
Shi Ming Tu, Sumit K. Subudhi, Ana Aparicio, Ioannis Alafis, Brian F. Chapin, Xuemei Wang, Myrto Boukovala, Paul G. Corn, Nicholas Spetsieris, John C. Araujo, Justin A. Weldon, Eleni Efstathiou, Jennifer Wang, Lisa Pruitt, Christopher J. Logothetis, Amado J. Zurita, John Papadopoulos, John J. Davis
Publikováno v:
European Journal of Cancer. 157:259-267
Background Intermittent androgen deprivation therapy (ADT) in biochemically recurrent castration-naive prostate cancer is non-inferior to continuous therapy. We hypothesised that finite-duration abiraterone acetate plus prednisone (Abi +P) added to A
Autor:
Yasushi Shimada, Takashi Hoshino, Tamon Nagashima, Toshio Uraoka, Takashi Ueno, Atsushi Naganuma, Hiroki Tojima, Masashi Namikawa, Hitoshi Takagi, Ken Sato, Daichi Takizawa, Takeshi Hatanaka, Hirotaka Arai, Satoshi Takakusagi, Satoru Kakizaki
Publikováno v:
Internal Medicine
Objective Chronic hepatitis C virus (HCV) infection carries a residual risk of hepatocarcinogenesis even after viral elimination, so appropriate follow-up is necessary. The present study investigated the current hospital visits and hepatocarcinogenes
Autor:
Mei Zhao, Min Liu, Peng Zhao, Yi Huang, Shisi Huang, Shuangshuang Wen, Ying Chen, Bo Deng, Dan Ma, Yan Zhang, Ming Ni, Yan Li, Yun Zhan, Yanju Li, Xiao Chai, Fengqi Zhang, Qian Kang, Jishi Wang, Qin Fang
Publikováno v:
Annals of Hematology
This study aimed to evaluate the efficacy and safety of venetoclax plus azacitidine and donor lymphocyte infusion (DLI) in treating patients with relapsed acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (allo-HSC
Autor:
Susan M. Webb, Alicia Santos, Anna Aulinas, Mary E. McCaul, Richard S. Lee, Gary S. Wand, Eugenia Resmini, Jenny L. Carey, Peter P. Zandi
Publikováno v:
J Clin Endocrinol Metab
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
ContextChronic exposure to glucocorticoids (GCs) or stress increases the risk of medical disorders, including cardiovascular and neuropsychiatric disorders. GCs contribute to accelerated aging; however, while the link between chronic GC exposure and
Autor:
Angela Dispenzieri, M Hasib Sidiqi, David Dingli, Prashant Kapoor, Francis K. Buadi, Nelson Leung, Martha Q. Lacy, Shaji Kumar, Morie A. Gertz, Robert A. Kyle, Suzanne R. Hayman, Eli Muchtar, Miriam Hobbs, Dragan Jevremovic, Taxiarchis Kourelis, Ronald S. Go, Wilson I. Gonsalves, S. Vincent Rajkumar, Rahma Warsame, Abdullah S. Al Saleh
Publikováno v:
American Journal of Hematology. 96:1131-1136
Multiple myeloma (MM) remains an incurable disease despite incorporation of novel agents. Venetoclax, a B-cell lymphoma 2 (BCL-2) inhibitor is approved for some hematologic malignancies but not yet for MM, although clinical trials have shown efficacy
Autor:
Xin Li, Ting Yuan, Rui Sun, Xia Xiong, Yunxiong Wei, Hairong Lyu, Xin Jin, Ming-Feng Zhao, Wenyi Lu, Xiaoyuan He, Tongtong Sun
Publikováno v:
Cancer Science
Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are usually associated with poor outcomes, especially in high‐risk AML/MDS. Allogeneic hematopoietic stem cell transplantation (allo‐HSCT) is the only curative option for patients su